Alpha Teknova, Inc.

Alpha Teknova, Inc. (NASDAQ: TKNO - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the

Alpha Teknova NASDAQ: TKNO raised its 2026 revenue guidance after reporting a second consecutive quarter of record revenue, as demand for custom products from biopharma, life science tools and diagnostics customers helped drive 22% year-over-year growth.

Alpha Teknova, Inc. (TKNO) Q3 2026 Earnings Call Transcript

Alpha Teknova (TKNO) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.

Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year Company raises 2026 revenue guidance to $46-48 million Strengthened balance sheet with $46 million public equity offering completed in October 2026 HOLLISTER, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diag…

We remain encouraged by the operational performance of the Micro cap companies held in portfolios. TWST shares surged as a strong fiscal 3Q highlighted accelerating demand across several of the company's end markets. TKNO management responded to the stronger first half by substantially raising its full-year revenue outlook.

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

HOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2026, on Wednesday, November 4, 2026, following the close of market.

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and o…

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in…

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing of a preliminary prospectus supplement, preliminary unaudited financial results for the three months ended September 30, 2026.

What happened Alpha Teknova, Inc. (NASDAQ: TKNO) is making it easier for cell-therapy developers to use PluriFreeze without rebuilding the same regulatory package from scratch. Pluristyx is completing a Type II Drug Master File for the cryopreservation system. Authorized customers can cross-reference the confidential chemistry, manufacturing and controls information in Investigational New Drug and Biologics

Teknova and Pluristyx announce a Type II FDA Drug Master File for the PluriFreeze™ cryopreservation system, now available to developers for cross-reference

Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Icon (NASDAQ: ICLR - Get Free Report) and Alpha Teknova (NASDAQ: TKNO - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends. Profitability This table compares Icon and Alpha Teknova's net

Squarepoint Ops LLC reduced its stake in shares of Alpha Teknova, Inc. (NASDAQ: TKNO) by 71.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,948 shares of the company's stock after selling 88,412 shares during the quarter. Squarepoint

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Teknova's Fill-Tek™ Dispensing System fills single-use bag orders across multiple sizes and quantities as a single lot, with no added turnaround time.

Alpha Teknova NASDAQ: TKNO Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve.

Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.